Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alios BioPharma, has signed an exclusive worldwide licensing agreement with Versitech to develop technology targeting influenza viruses besides manufacturing and commercializing novel medicines to treat influenza.
Subscribe to our email newsletter
In addition, the companies also entered two other influenza-related, non-exclusive license agreements and a sponsored research agreement.
As per the deal, Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.
Alios BioPharma founder and CEO Lawrence M Blatt said the compounds and technology derived from this deal would provide novel therapeutic options to help in the improvement of influenza virus-infected patients.